Aside from being a prognostic biomarker and therapeutic target, HER2 also interplays with noncoding RNAs that, when dysregulated, can alter the expression levels of HER2 and, ultimately, lead to chemoresistance and progression in ovarian cancer. This evidence concerns the gene ERBB2 and ovarian cancer.